Lee Yuchun 4

4 · VERTEX PHARMACEUTICALS INC / MA · Filed Jan 25, 2023

Form 4

Period: 2023-01-23

Director

Transactions

Exercise/Conversion
Common Stock
2023-01-23$72.14/sh+2,129$153,586→ 4,004 total
Exercise/Conversion
Common Stock
2023-01-24$72.14/sh+4,000$288,560→ 5,875 total
Sale
Common Stock
2023-01-24$312.29/sh−2,511$784,160→ 3,364 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-01-23−2,129→ 13,429 total
Exercise: $72.14Exp: 2024-05-31→ Common Stock (2,129 underlying)
Sale
Common Stock
2023-01-23$312.02/sh−2,129$664,291→ 1,875 total
Sale
Common Stock
2023-01-24$313.36/sh−1,489$466,593→ 1,875 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-01-24−4,000→ 9,429 total
Exercise: $72.14Exp: 2024-05-31→ Common Stock (4,000 underlying)

Footnotes (6)

[F1]Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
[F2]Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
[F3]Open market sales reported on this line occurred at a weighted average price of $312.02 (range $312.00 to $312.17).
[F4]Open market sales reported on this line occurred at a weighted average price of $312.29 (range $312.00 to $312.92).
[F5]Open market sales reported on this line occurred at a weighted average price of $313.36 (range $313.00 to $313.73).
[F6]Fully vested.

Documents

1 file